The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HILS | +38.07% | N/A | N/A | -100% |
| S&P | +12.57% | +87.93% | +13.44% | +43% |
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is used to identify biomarkers in its clinical programs to target a specific patient segment. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
No news articles found for Tharimmune.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $15.64M | 448.9% |
| Market Cap / Employee | $7.82M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$2.10M | 44.6% |
| EBITDA | -$2.09M | 45.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.61M | 59.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.20M | 142.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -159.36% | 98.4% |
| Return On Invested Capital | -206.37% | -214.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.86M | 35.2% |
| Operating Free Cash Flow | -$1.86M | 35.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.86 | 2.05 | -5.02 | 32.63 | 7943.48% |
| Price to Tangible Book Value | 0.86 | 2.05 | -5.02 | 32.63 | 7943.21% |
| Enterprise Value to EBITDA | -0.12 | -1.16 | -1.99 | -4.93 | -2324.06% |
| Return on Equity | -233.7% | -400.4% | -340.3% | -225.0% | -50.50% |
| Total Debt | $0.00M | $0.52M | $0.33M | $0.20M | 142.04% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
